February 28, 2023, Three doses (10 mg, 20 mg, 40 mg) of Esomeprazole magnesium for delayed release oral suspension（卫艾宁®）,  the imported finished product which is licensed from Cipla Ltd. , were formally approved by the NMPA, the National Medical Products Administration. It is approved for the treatment of gastroesophageal reflux disease, eradication of Helicobacter pylori in combination with appropriate antimicrobial therapy, and patients requiring sustained NSAIDs (non-steroidal anti-inflammatory drugs) and etc. 

卫艾宁® (Esomeprazole magnesium for delayed release oral suspension) is the proton pump inhibitor that is approved in pediatric patients by the US FDA. It is also included in the second batch of products for encouraging the development of the proposed children's drug list. As an international high-quality product manufactured by the facility successfully passed the inspection by the US FDA, 卫艾宁® (Esomeprazole magnesium for delayed release oral suspension) will provide the best PPI treatment options for children and special patients with dysphagia problem in China.

According to the sales data in Menet, the total sales of PPI products in sample hospitals in China exceeded RMB 5.6 billion in 2021. Among them, Esomeprazole has the best sales performance, up to RMB 1.36 billion, with a market share of 24% of all PPI sales and rapid market growth, and has been the best-selling PPI in the world and in China for many years.

Compared with the general oral dosage form, the enteric-coated dry suspension is convenient for administration, which is beneficial to the children and the patients with dysphagia. After preparation, the drug and water are completely combined in a pasty liquid, which perfectly fits the dietary needs of the patients with dysphagia, and is convenient for gavage, nasal feeding or oral feeding. In addition, the product is packaged according to the order of dosage, and dosage is accurately administered once a day with good taste, which greatly improves the patient's compliance.

卫艾宁® Prepared Dissolution Photo

About Cipla

Founded in 1935, Cipla is a world-leading pharmaceutical company focused on complex generic drugs. Cipla uses sophisticated technology platforms to produce more than 50 formulations and more than 1500 products at forty-four manufacturing sites worldwide to meet the needs of more than 80 markets. According to IQVIA data, Cipla ranks top three in the Indian pharmaceutical industry, top three in the private pharmaceutical market in South Africa, and one of the most commonly prescribed generic drug manufacturers in the United States.

About  Beimei pharmaceutical

Beimei pharmaceutical  focuses on the field of pediatric prescription medicines, aiming to become a new pharmaceutical enterprise integrating R&D, global licensing, manufacture, marketing and distribution, and taking independent R&D and global license in pediatric products as the strategic direction. At present, the product pipeline covers respiratory system, anti-infection (antibacterial), nervous system, digestive system, and other fields.Beimei pharmaceutica is committed to providing Chinese pediatric patients with convenient, accurate, excellent taste and high quality products.